Targeting Glutathione S-transferase M4 in Ewing sarcoma

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Ewing sarcoma is a pediatric bone and soft tissue cancer with a poor prognosis for metastatic or therapy-resistant cases.
• High expression of glutathione S-transferase M4 (GSTM4) in primary tumors correlates with adverse patient outcomes.
• GSTM4 plays a role in oncogenic transformation and chemotherapy resistance in Ewing sarcoma cells.

Purpose of the Study:

• To investigate GSTM4 as a specific therapeutic target in Ewing sarcoma.
• To evaluate the efficacy of pharmacological inhibition and GSTM4-activated agents against Ewing sarcoma.
• To elucidate the mechanism by which GSTM4 promotes tumor survival.

Main Methods:

• RNA-sequencing analysis of Ewing sarcoma cells and public datasets.
• Pharmacological inhibition of GSTM4 using 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio) hexanol (NBDHEX).
• Assessment of cell viability, proliferation, apoptosis, and xenograft tumor growth.
• Mechanistic studies involving Apoptosis Signal-regulating Kinase 1 (ASK1) and c-Jun N-terminal Kinase (JNK) signaling.

Main Results:

• GSTM4 is specifically upregulated in Ewing sarcoma.
• NBDHEX inhibited Ewing sarcoma cell proliferation and oncogenic transformation.
• Combined NBDHEX and etoposide demonstrated synergistic cytotoxicity, indicating GSTM4 inhibits apoptosis.
• GSTM4 interacts with ASK1, inhibiting the JNK axis.
• The GSTM4-activated agent JS-K reduced cell viability, xenograft tumor growth, and improved survival in mice.

Conclusions:

• GSTM4 is a novel therapeutic target for Ewing sarcoma.
• Targeting GSTM4, through inhibition or activation of specific agents, offers a promising strategy.
• Combination therapies involving GSTM4-targeting agents may enhance efficacy and specificity in treating Ewing sarcoma.